LAM
PVLA

Lebenthal Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Lebenthal Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$26K Hold
125
– – ﹤0.01% 322
2016
Q4 		$14K Hold
125
– – ﹤0.01% 316
2016
Q3 		$18K Hold
125
– – ﹤0.01% 633
2016
Q2 		$16K Buy
+125
New +$19.2K ﹤0.01% 324

Other funds holding PVLA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lebenthal Asset Management's PVLA Position: Q1 2017 in Review

Lebenthal Asset Management held its Palvella Therapeutics (PVLA) position steady in Q1 2017 at 125 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #322.

Lebenthal Asset Management first reported a position in PVLA in Q2 2016 and has held it in 4 quarters since. 27 funds tracked by Wall St. Rank hold PVLA as of Q1 2017.

  • Lebenthal Asset Management held 125 shares of Palvella Therapeutics worth $26K as of Q1 2017.
  • Lebenthal Asset Management left its Palvella Therapeutics share count unchanged in Q1 2017.
  • Palvella Therapeutics made up ﹤0.01% of Lebenthal Asset Management's portfolio in Q1 2017, its #322 holding.
  • Lebenthal Asset Management first reported a position in Palvella Therapeutics in Q2 2016 and has held it in 4 quarters since.
  • 27 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2017.

Based on Lebenthal Asset Management's 13F filing for Q1 2017, filed 15 May 2017.